U R O – V A X O M 

Facts about Uro-Vaxom

Uro-Vaxom is an immune stimulating agent. It differs from treatment with antibiotics in that the Uro-Vaxom strengthens the immune response of the urinary tract. One Uro-Vaxom capsule contains 6mg of lyophilized bacterial lysates of Escherichia coli. It also contains inert excipients pregelatinized maize starch, magnesium silicate, magnesium stearate, sodium glutamate, mannitol, gelatin, ferric oxides, and titanium dioxide.

How Uro-Vaxom Works

Uro-Vaxom, in humans, stimulates T-lymphocytes, induces production of endogenous interferon and increases the Secretory Immunoglobulin A (sIgA), level in urine. Secretory Immunoglobulin A is an antibody which plays a critical role in mucosal urinary immunity. It protects against microbes that multiply in body secretions.

In animals it has been reported to provide a protective effect against experimental infections, a stimulation of macrophages, β-lymphocytes and immunocompetent cells, as well as an increase in IgA level in intestinal secretions

Benefits

>  Prevention of recurrent lower urinary tract infections

> Immunotherapy

> Co medication in the treatment of acute urinary tract infections

Dosage and Administration

> Preventive treatment and/or consolidation therapy:  1 capsule daily on an empty stomach for three (3) consecutive months.

> Treatment during acute episodes  – 1 capsule daily on an empty stomach as co medication to conventional antimicrobial therapy until disappearance of the symptoms for at least ten (10) consecutive days.

> Presentation – in packs 90 capsules

In order to establish a full immune response it is important to continue the treatment over 90 days, even when symptoms have ceased.  Patients with a very weak immune system might need to be treated over longer periods of time than the initial 90 day course.  To refresh the memory of the immune response, the following protocol is 90 initial treatment, 90 days off, then 10 days on & 20 days off.  Repeat this 10 days on & 20 days off for the next three (3) months.

There has been no known case of overdosage nor of drug interaction up to now.

Limitations for use

> The efficacy and safety of Uro-Vaxom have not been established in children below four (4) years.

> When considering its effects on one’s ability to drive and use machines – Uro-Vaxom is presumed to be safe and unlikely to produce a sedative effect.

> It is contraindicated when there is known hypersensitivity towards the constituents of Uro-Vaxom

Pregnancy and Lactation

Reproduction studies in animals have not demonstrated any risk to the foetus, but controlled studies in pregnant women are not yet available. With regard to breast-feeding, no specific studies have been performed and no data have been reporte to date. Also, as there have been no studies undertaken during the first three (3) months of pregnancy. Uro-Vaxom should not be taken during this time.

Adverse effects

The overall incidence of adverse effects in clinical trials lies around 4%.  The most frequent complaints reported include – gastrointestinal troubles (diarrhoea, nausea, abdominal pain), dermatological reactions (pruritus, skin rash), as well as generalized problems such as slight fever.

In the preclinical safety data – extensive toxicity studies have not revealed any toxic effects.

Other overall help

Hygiene – (wash/shower, clean hot washed underwear), sexual abstinence during acute episodes, drink lots of fluids, wear appropriate clothing in cold weather, take vitamin C supplements.

Or see all Testimonials.